Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.

ABSTRACT: Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting. Nine patients received tafasitamab and lenalidomide immediately preceding CAR-T. Median (first quartile [Q1]-third quartile [Q3]) follow-up time since tafasitamab initiation was 26.1 (18.0-28.0) and after CAR-T was 9.3 (1.9-16.7) months. O

SUBMITTER: Epperla N 

PROVIDER: S-EPMC11755875 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature